Oculis Strengthens Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma

...

02 March, 2022

Oculis appoints Dr. Bastian Dehmel as Chief Development Officer

08 February, 2022

Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)

05 January, 2022

Oculis Announces Patient Dosing in its First Phase 3 (DIAMOND Study – DIAbetic Macular edema patients ON a Drop) with OCS-01, a Novel, Investigational Topical Eye Drop Treatment for Diabetic Macular Edema (DME)

12 November, 2021

Oculis Appoints Dr. Joanne Chang as Global Chief Medical Officer and Opens Hong Kong Office to broaden its footprint and build a strong Asia/China presence

07 October, 2021

Oculis Announces Positive Data from Two Proof-of-Concept Phase 2 Trials with OCS-02, a Novel Topical TNF alpha Antagonist, in Dry Eye Disease and Acute Anterior Uveitis, Presented at ARVO 2021

11 May, 2021

Oculis Announces an Oversubscribed US$57 million Series C Financing

04 May, 2021

Oculis to Present Recent Progress in its Portfolio at Upcoming Investor Conferences

24 November, 2020

Oculis appoints David Jacobs, M.D. as Chief Development Officer

22 October, 2020

Oculis announces presentation of OCS-01 Phase 2 DME study at EURETINA 2020

05 October, 2020